FUNI: Hypha Labs, Inc. Stock

SIC 8734 – Testing Laboratories

Valuation
Market Cap ($M) n/a
Enterprise Value ($M) n/a
Book Value ($M) -1.23
Book Value / Share -0.01
Price / Book n/a
NCAV ($M) -1.31
NCAV / Share -0.01
Price / NCAV n/a

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -1.64
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.12
Current Ratio 0.12

Balance Sheet (mrq) ($M)
Current Assets 0.18
Assets 0.26
Liabilities 1.49
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -1.76
Net Income -0.79
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -1.03
Cash from Investing 2.15
Cash from Financing -1.29

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For Quarterly Period Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2025-01-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)

Similar Companies
BUDZ – WEED, Inc. CBIH – Cannabis Bioscience International Holdings, Inc.
FNAM – Evolutionary Genomics, Inc. LUNA – Luna Innovations Incorporated
MRPI – Mera Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io